Updated on 24 July 2014
Singapore: Australia's healthcare company focused on investing in and developing next generation technologies, Admedus, has increased its ownership in Admedus Vaccines, the platform vaccine development company led by Professor Ian Frazer from, 50.1 percent to 66.3 percent.
Admedus Vaccines was founded in 2000 by the founder inventor Professor Ian Frazer as a private unlisted company, to develop and commercialise patented technology for improving immune responses to DNA vaccines licensed by UniQuest and developed at the University of Queensland.
Admedus Vaccines has 6 granted US patents protecting its codon optimisation DNA technology, which enhances protein expression in the cell or tissue targeted and results in an improved humoral response.
"This is in-keeping with our planned use of funds from the recent capital raising and reflects the ongoing positive progress being made by Professor Ian Frazer and the therapeutic vaccines development team" said Mr Lee Rodne, CEO, Admedus.
Admedus has announced positive interim results from Phase I Herpes Simplex 2 (HSV-2) therapeutic vaccine trial. The company is scheduled to report additional data this quarter, once confirmatory assays have been completed. The current investment, ahead of these results, is designated to fund the planned Phase II HSV-2 study which is due to be initiated by the end of 2014.